Karyopharm Therapeutics Inc. diskutieren
Karyopharm Therapeutics Inc.
WKN: A1W77U / Symbol: KPTI / Name: Karyopharm / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
Ausbruch...
Mit dem heutigen Kaufsignal sind bald Kurse von über 30 Euro drin.
karyopharm th.
nachkaufen???
we will see
kyron7htx stimmt der fundamentalen Bewertung mit dem Ergebnis 'translation missing: de.models.ratings.theoretical_rating' nicht zu
Volltreffer.
kyron7htx stimmt am 02.10.2015 der fundamentalen Bewertung mit dem Ergebnis translation missing: de.models.ratings.theoretical_rating nicht zu.
Karyopharm - alles oder nichts!
Bei Karyopharm handelt es sich um ein Biotechnologie-Unternehmen, dessen Aktie zuletzt arg verprügelt wurde. Grund waren nicht ganz so berauschende Daten zum bisher wichtigsten Medikament. Aufgrund der schlechten Daten haben manche Anleger die komplette Technologie des Unternehmens in Zweifel gezogen. Ich sehe dies jedoch nach vielen informativen Gesprächen mit Branchenkennern etwas anders und hege keinerlei Zweifel an der Technologieplattform. Daher traue ich der Aktie im Laufe der Zeit ein Comeback zu. Aber Vorsicht, hochspekulativ!!
bio-Therapeutika
folgen
Karyopharm with an evolving and diverse pipeline
The company’s main focuses can be broken down into 4 areas of therapy:
hematological malignancies, solid tumors, additional oncology programs,
and an “others” category. The company’s lead drug candidate is Selinexor, which is currently in 4 trials for hematological malignancies and 3 trials for solid tumors.
In April of 2017, at the American Association for Cancer Research annual meeting the company reported a 28.6% overall response rate observed in the ongoing Phase 2b SADAL study. Provided that the data is positive, the company will seek a NDA submission in 2018. Lastly, solid tumors is the third leading indication for Selinexor. In March of 2017, the company completed enrollment in the Phase 2 portion of the randomized Phase 2/3 SEAL study evaluating Selinexor versus placebo in patients with advanced liposarcoma after at least one prior therapy. The company will report the top-line data from the Phase 2 portion of this study in mid-2017.
Wall Street seems to have a positive view on KPTI’s prospects with 7 buy ratings, 0 hold ratings, and 0 sell recommendations. The consensus price target currently sits at just over $15.00 a share, which represents an upside of approximately 50%. The latest recommendation comes via Cantor Fitzgerald on May 15th, 2017. The firm reiterated their overweight rating and kept their price target at $18. Cantor stated that they think the presentation at the European Hematology Association could bring about support for KPTI’s DLBCL program. On April 7th, 2017, Jefferies reiterated a buy rating on the stock and kept their price target at $17.
Biotechnologie und medizinische SecteurRecherche
Biotechnologie und medizinische SecteurRecherche
Karyopharm Therapeutics, Inc. ist eine klinische Phase - Pharma - Unternehmen, entdeckt, entwickelt und vermarktet Medikamente Krebs und anderen schweren Krankheiten zu behandeln.
Das Unternehmen beabsichtigt , mit Bortezomib (Velcade) und niedrig dosiertem Dexamethason (BOSTON) in Patienten mit multiplem Myelom einer Phase - 3 - Dreh randomisierten Studie selinexor in Kombination zu initiieren.
Karyopharm Therapeutics wurde von Joseph Araujo, Ronald A. DePinho, Pamela A Silber Giulio Draetta Michael G. Kauffman und Sharon Shacham Dezember 2008 22, gegründet und ist in Newton, MA ansässig.
Anzahl der Mitarbeiter: 108 Personen.
Biotechnologie und medizinische SecteurRecherche
Karyopharm with an evolving and diverse pipeline
The company’s main focuses can be broken down into 4 areas of therapy:
hematological malignancies, solid tumors, additional oncology programs,
and an “others” category. The company’s lead drug candidate is Selinexor, which is currently in 4 trials for hematological malignancies and 3 trials for solid tumors.
In April of 2017, at the American Association for Cancer Research annual meeting the company reported a 28.6% overall response rate observed in the ongoing Phase 2b SADAL study. Provided that the data is positive, the company will seek a NDA submission in 2018. Lastly, solid tumors is the third leading indication for Selinexor. In March of 2017, the company completed enrollment in the Phase 2 portion of the randomized Phase 2/3 SEAL study evaluating Selinexor versus placebo in patients with advanced liposarcoma after at least one prior therapy. The company will report the top-line data from the Phase 2 portion of this study in mid-2017.
Wall Street seems to have a positive view on KPTI’s prospects with 7 buy ratings, 0 hold ratings, and 0 sell recommendations. The consensus price target currently sits at just over $15.00 a share, which represents an upside of approximately 50%. The latest recommendation comes via Cantor Fitzgerald on May 15th, 2017. The firm reiterated their overweight rating and kept their price target at $18. Cantor stated that they think the presentation at the European Hematology Association could bring about support for KPTI’s DLBCL program. On April 7th, 2017, Jefferies reiterated a buy rating on the stock and kept their price target at $17.
Mit
einem weiteren Anstieg ist zu rechnen.
Neueste Beiträge
Bankster in Agba Acquisition Ltd. diskutieren, Agba Group Holding Ltd.